These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33659041)

  • 1. Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8+ T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model.
    Zaidi AH; Kelly RJ; Gorbunova A; Omstead AN; Salvitti MS; Zheng P; Kosovec JE; Lee S; Ayazi S; Babar L; Finley GG; Goel A; Jobe BA
    Oncotarget; 2021 Feb; 12(4):292-303. PubMed ID: 33659041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of regulatory ISGs enhances the anti-melanoma efficacy of STING agonists.
    Filderman JN; Taylor JL; Wang J; Zhang Y; Singh P; Ross MA; Watkins SC; Nedal Al Bzour A; Karapetyan L; Kalinski P; Storkus WJ
    Front Immunol; 2024; 15():1334769. PubMed ID: 38312842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking Tim-3 enhances the anti-tumor immunity of STING agonist ADU-S100 by unleashing CD4
    Luo J; Pang S; Hui Z; Zhao H; Xu S; Yu W; Yang L; Sun Q; Hao X; Wei F; Wang J; Ren X
    Theranostics; 2023; 13(14):4836-4857. PubMed ID: 37771774
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer.
    Esteves AM; Papaevangelou E; Dasgupta P; Galustian C
    Front Oncol; 2021; 11():621550. PubMed ID: 33777767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
    Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
    Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnitude of Therapeutic STING Activation Determines CD8
    Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
    Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of STING inhibits cervical cancer tumor growth through enhancing the anti-tumor immune response.
    Shi F; Su J; Wang J; Liu Z; Wang T
    Mol Cell Biochem; 2021 Feb; 476(2):1015-1024. PubMed ID: 33141310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal Delivery of MIW815 (ADU-S100) for Potentiated STING Activation.
    Ji N; Wang M; Tan C
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer.
    Lee SJ; Yang H; Kim WR; Lee YS; Lee WS; Kong SJ; Lee HJ; Kim JH; Cheon J; Kang B; Chon HJ; Kim C
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34145029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
    Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
    Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective STING stimulation in dendritic cells primes antitumor T cell responses.
    Jneid B; Bochnakian A; Hoffmann C; Delisle F; Djacoto E; Sirven P; Denizeau J; Sedlik C; Gerber-Ferder Y; Fiore F; Akyol R; Brousse C; Kramer R; Walters I; Carlioz S; Salmon H; Malissen B; Dalod M; Piaggio E; Manel N
    Sci Immunol; 2023 Jan; 8(79):eabn6612. PubMed ID: 36638189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models.
    Berger G; Knelson EH; Jimenez-Macias JL; Nowicki MO; Han S; Panagioti E; Lizotte PH; Adu-Berchie K; Stafford A; Dimitrakakis N; Zhou L; Chiocca EA; Mooney DJ; Barbie DA; Lawler SE
    Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2111003119. PubMed ID: 35787058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation.
    Du SS; Chen GW; Yang P; Chen YX; Hu Y; Zhao QQ; Zhang Y; Liu R; Zheng DX; Zhou J; Fan J; Zeng ZC
    Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1243-1255. PubMed ID: 34986380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity.
    Hernandez-Franco JF; Jan IM; Elzey BD; HogenEsch H
    NPJ Vaccines; 2024 Aug; 9(1):149. PubMed ID: 39152131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models.
    Takahashi-Ruiz L; Fermaintt CS; Wilkinson NJ; Chan PYW; Mooberry SL; Risinger AL
    Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
    Meric-Bernstam F; Sweis RF; Kasper S; Hamid O; Bhatia S; Dummer R; Stradella A; Long GV; Spreafico A; Shimizu T; Steeghs N; Luke JJ; McWhirter SM; Müller T; Nair N; Lewis N; Chen X; Bean A; Kattenhorn L; Pelletier M; Sandhu S
    Clin Cancer Res; 2023 Jan; 29(1):110-121. PubMed ID: 36282874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic immunotherapy using ADU-S100-modified nanoparticles to treat triple-negative breast cancer.
    Ge T; Ge W; Zhang L; Yu G; Li Y; Sun L; Dong F; Yao Z; Shi L; Wang Y
    Nanomedicine (Lond); 2023 Apr; 18(9):755-767. PubMed ID: 37306248
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma.
    Hajiabadi S; Alidadi S; Montakhab Farahi Z; Ghahramani Seno MM; Farzin H; Haghparast A
    Front Immunol; 2023; 14():1258691. PubMed ID: 37901237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.